Correlation between phosphatase of regenerating liver-3 and portal vein tumor thrombus of hepatocellular carcinoma

doi:10.3877/cma.j.issn.2095-3232.2015.02.013

Abstract

Abstract:

Objective

To explore the correlation between phosphatase of regenerating liver-3 (PRL-3) and portal vein tumor thrombus in hepatocellular carcinoma (HCC).

Methods

Clinical data of 248 patients with HCC undergoing hepatectomy in the First People's Hospital of Foshan between December 2003 and December 2008 were retrospectively analyzed. The informed consents of all patients were obtained and the local ethical committee approval had been received. Among the 248 patients, 193 were males and 55 were females with the age ranging from 18 to 75 years old and the median of 48 years old. Forty-five cases were complicated with portal vein tumor thrombus. The expression of PRL-3 in HCC and portal vein tumor thrombus were observed by immunohistochemistry. The correlation between the expression of PRL-3 and the clinicopathological parameters of HCC patients and its significance in portal vein tumor thrombus formation were analyzed. The analysis on the correlation between the expression of PRL-3 and the clinicopathological parameters of HCC was conducted using χ² test and the analysis on the risk factors associated with portal vein tumor thrombus formation was conducted using Logistic regression analysis.

Results

The positive expression rate of PRL-3 in HCC and portal vein tumor thrombus was 70% (174/249) and 98% (44/45)respectively, and the positive expression rate in portal vein tumor thrombus was significantly higher than that in HCC (χ²=15.253, P<0.05). The positive expression of PRL-3 was associated with the serum AFP, tumor diameter, histological differentiation of tumor, portal vein tumor thrombus formation, tumor TNM staging and early recurrence (χ²=4.836, 7.186, 4.226, 5.357, 13.862, 10.824; P<0.05). The positive expression of PRL-3 was the risk factor for portal vein tumor thrombus formation (OR=2.674, P<0.05).

Conclusions

PRL-3 expression increases in HCC portal vein tumor thrombus and positive expression of PRL-3 may be closely associated with the invasion and metastasis of HCC.

Key words: Carcinoma, hepatocellular, Portal vein, Neoplastic cells, circulating, Neoplasm metastasis

Dehao Huang, Shuying Su, Yunfeng Cai, Geng Zhang. Correlation between phosphatase of regenerating liver-3 and portal vein tumor thrombus of hepatocellular carcinoma[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2015, 04(02): 113-118.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2015.02.013

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2015/V04/I02/113

Figures/Tables 3

References 16

[1]	Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 127(12): 2893-2917.
[2]	Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
[3]	Fleming CJ, Andrews JC, Wiseman GA, et al. Hepatic vein tumor thrombus as a risk factor for excessive pulmonary deposition of microspheres during TheraSphere therapy for unresectable hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2009, 20(11):1460-1463.
[4]	Giorgio A, Di Sarno A, de Stefano G, et al. Hepatocellular carcinoma with cirrhosis: are patients with neoplastic main portal vein invasion eligible for percutaneous radiofrequency ablation of both the nodule and the portal venous tumor thrombus?[J]. AJR Am J Roentgenol, 2009, 193(4):948-954.
[5]	Inoue Y, Hasegawa K, Ishizawa T, et al. Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma?[J]. Surgery, 2009, 145(1):9-19.
[6]	Lu ZH, Shen F, Yan ZL, et al. Treatment of portal vein tumor thrombus of hepatocellular carcinoma with percutaneous laser ablation[J]. J Cancer Res Clin Oncol, 2009, 135(6):783-789.
[7]	Hassan NM, Hamada J, Kameyama T, et al. Increased expression of the PRL-3 gene in human oral squamous cell carcinoma and dysplasia tissues[J]. Asian Pac J Cancer Prev, 2011, 12(4):947-951.
[8]	Jian M, Nan L, Guocheng J, et al. Downregulating PRL-3 inhibit migration and invasion of lung cancer cell via RhoA and mDia1[J]. Tumori, 2012, 98(3):370-376.
[9]	Liu H, Al-aidaroos AQ, Wang H, et al. PRL-3 suppresses c-Fos and integrin α2 expression in ovarian cancer cells[J]. BMC Cancer, 2013(13):80.
[10]	Lou X, Liu Y, Lei JY, et al. Overexpression of phosphatase regenerating liver 3 in oesophageal squamous cell carcinoma associated with metastasis and its comparison with phosphatase regenerating liver 1[J]. Cell Biol Int, 2012, 36(8):759-763.
[11]	Xing X, Lian S, Hu Y, et al. Phosphatase of regenerating liver-3 (PRL-3) is associated with metastasis and poor prognosis in gastric carcinoma[J]. J Transl Med, 2013(11):309.
[12]	Mayinuer A, Yasen M, Mogushi K, et al. Upregulation of protein tyrosine phosphatase type IVA member 3 (PTP4A3/PRL-3) is associated with tumor differentiation and a poor prognosis in human hepatocellular carcinoma[J]. Ann Surg Oncol, 2013, 20(1):305-317.
[13]	Wittekind C. 2010 TNM system: on the 7th edition of TNM classification of malignant tumors[J]. Pathologe, 2010, 31(5):331-332.
[14]	Rios P, Li X, Köhn M. Molecular mechanisms of the PRL phosphatases[J]. FEBS J, 2013, 280(2):505-524.
[15]	Tamagawa H, Oshima T, Yoshihara K, et al. The expression of the phosphatase regenerating liver 3 gene is associated with outcome in patients with colorectal cancer[J]. Hepatogastroenterology, 2012, 59(119):2122-2126.
[16]	Ustaalioglu BB, Bilici A, Barisik NO, et al. Clinical importance of phosphatase of regenerating liver-3 expression in breast cancer[J]. Clin Transl Oncol, 2012, 14(12):911-922.

临床病理学参数		例数	PRL-3蛋白阳性表达		χ ²值	P值
临床病理学参数		例数	例数	百分率（%）	χ ²值	P值
性别		?	?	?	2.172	>0.05
?	男	193	131	68	?	?
?	女	55	43	78	?	?
年龄（岁）		?	?	?	0.259	>0.05
?	<50	138	95	69	?	?
?	≥50	110	79	72	?	?
HBsAg		?	?	?	1.225	>0.05
?	阴性	59	38	64	?	?
?	阳性	189	136	72	?	?
AFP(μg/L)		?	?	?	4.836	<0.05
?	<400	111	70	63	?	?
?	≥400	137	104	76	?	?
肿瘤直径(cm)		?	?	?	7.186	<0.05
?	<5	99	60	61	?	?
?	≥5	149	114	77	?	?
肿瘤组织学分化程度		?	?	?	4.226	<0.05
?	高或中分化	150	98	65	?	?
?	低分化	98	76	78	?	?
门静脉癌栓形成		?	?	?	5.357	<0.05
?	无	203	136	67	?	?
?	有	45	38	84	?	?
TNM分期		?	?	?	13.862	<0.05
?	Ⅰ～Ⅱ	83	47	57	?	?
?	Ⅲa	78	55	71	?	?
?	Ⅲb～Ⅳ	87	72	83	?	?
早期复发		?	?	?	10.824	<0.05
?	无	156	98	63	?	?
?	有	92	76	83	?	?

临床病理学参数		例数	PRL-3蛋白阳性表达		χ ²值	P值
临床病理学参数		例数	例数	百分率（%）	χ ²值	P值
性别		?	?	?	2.172	>0.05
?	男	193	131	68	?	?
?	女	55	43	78	?	?
年龄（岁）		?	?	?	0.259	>0.05
?	<50	138	95	69	?	?
?	≥50	110	79	72	?	?
HBsAg		?	?	?	1.225	>0.05
?	阴性	59	38	64	?	?
?	阳性	189	136	72	?	?
AFP(μg/L)		?	?	?	4.836	<0.05
?	<400	111	70	63	?	?
?	≥400	137	104	76	?	?
肿瘤直径(cm)		?	?	?	7.186	<0.05
?	<5	99	60	61	?	?
?	≥5	149	114	77	?	?
肿瘤组织学分化程度		?	?	?	4.226	<0.05
?	高或中分化	150	98	65	?	?
?	低分化	98	76	78	?	?
门静脉癌栓形成		?	?	?	5.357	<0.05
?	无	203	136	67	?	?
?	有	45	38	84	?	?
TNM分期		?	?	?	13.862	<0.05
?	Ⅰ～Ⅱ	83	47	57	?	?
?	Ⅲa	78	55	71	?	?
?	Ⅲb～Ⅳ	87	72	83	?	?
早期复发		?	?	?	10.824	<0.05
?	无	156	98	63	?	?
?	有	92	76	83	?	?

临床病理学参数		例数	门静脉癌栓形成		OR	95%CI	P值
临床病理学参数		例数	例数	百分率(%)	OR	95%CI	P值
性别		?	?	?	1.393	0.607～3.198	>0.05
?	男	193	37	19	?	?	?
?	女	55	8	15	?	?	?
年龄（岁）		?	?	?	0.804	0.417～1.552	>0.05
?	< 50	138	27	20	?	?	?
?	≥50	110	18	16	?	?	?
HBsAg		?	?	?	0.957	0.451～2.032	>0.05
?	阴性	59	11	19	?	?	?
?	阳性	189	34	18	?	?	?
AFP(μg/L)		?	?	?	1.594	0.816～3.115	>0.05
?	< 400	111	16	14	?	?	?
?	≥400	137	29	21	?	?	?
肿瘤直径(cm)		?	?	?	2.732	1.284～5.816	<0.05
?	< 5	99	10	10	?	?	?
?	≥5	149	35	23	?	?	?
肿瘤组织学分化程度		?	?	?	7.778	3.626～16.683	<0.05
?	高或中分化	150	10	7	?	?	?
?	低分化	98	35	36	?	?	?
PRL-3蛋白表达		?	?	?	2.674	1.134～6.305	<0.05
?	阴性	74	7	9	?	?	?
?	阳性	174	38	22	?	?	?

临床病理学参数		例数	门静脉癌栓形成		OR	95%CI	P值
临床病理学参数		例数	例数	百分率(%)	OR	95%CI	P值
性别		?	?	?	1.393	0.607～3.198	>0.05
?	男	193	37	19	?	?	?
?	女	55	8	15	?	?	?
年龄（岁）		?	?	?	0.804	0.417～1.552	>0.05
?	< 50	138	27	20	?	?	?
?	≥50	110	18	16	?	?	?
HBsAg		?	?	?	0.957	0.451～2.032	>0.05
?	阴性	59	11	19	?	?	?
?	阳性	189	34	18	?	?	?
AFP(μg/L)		?	?	?	1.594	0.816～3.115	>0.05
?	< 400	111	16	14	?	?	?
?	≥400	137	29	21	?	?	?
肿瘤直径(cm)		?	?	?	2.732	1.284～5.816	<0.05
?	< 5	99	10	10	?	?	?
?	≥5	149	35	23	?	?	?
肿瘤组织学分化程度		?	?	?	7.778	3.626～16.683	<0.05
?	高或中分化	150	10	7	?	?	?
?	低分化	98	35	36	?	?	?
PRL-3蛋白表达		?	?	?	2.674	1.134～6.305	<0.05
?	阴性	74	7	9	?	?	?
?	阳性	174	38	22	?	?	?

Please choose a citation manager

Content to export